07.01.2022 • NewsBASF

BASF to Continue Share Buyback Program

German chemicals giant BASF plans to launch a corporate share buyback program worth up to €3 billion, beginning this month and stretching over nearly two years, until Dec. 31, 2023 at the latest.

Implementation is subject to a renewed authorization by the annual general meeting on Apr. 29, 2022. Following this, the group’s corporate parent, BASF SE, will cancel all repurchased shares and reduce its share capital accordingly.

The last buyback, totaling 10% of share capital, was initially approved by the May 12, 2017 annual meeting but expires on May 11, 2022. The new share repurchase is planned to be carried out on the electronic trading platform of the Frankfurt Stock Exchange (Xetra).

BASF said the decision to continue repurchasing shares reflects the positive business development and its divestments over the course of 2022. From 1999 to 2008, the company repurchased shares for around €9.9 billion and reduced the number of outstanding shares by around 29% altogether.

In the newest incarnation, BASF said available capital will be returned to shareholders, capital structure optimized and earnings per share increased. The chemical producer said it will continue to prioritize organic growth in its use of capital, while acquisitions are “currently of lower relevance.”

Author: Dede Williams, Freelance Journalist

(c) BASF
(c) BASF

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.